zacks.com · 29 jun

ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome

Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.

seekingalpha.com · 29 jun

Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus

Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.

zacks.com · 29 jun

Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

benzinga.com · 26 jun

Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) regarding its drug DAYBU (trofinetide) for treating neurobehavioral symptoms of Rett syndrome in the European Union.

fool.com · 26 jun

Why Acadia Pharmaceuticals Stock Is Soaring Today

Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition to treat rare and underserved diseases.

investors.com · 26 jun

The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout

Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval of the Rett syndrome drug, Daybu.

businesswire.com · 26 jun

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by.

zacks.com · 5 jun

Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?